Announced Thu, 2 Jul · 13:56 IST
Ajanta Pharma Paithan facility gets VAI classification from US FDA
Regulatory & Legal View source PDF
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-0.2%1-day move
₹3345.10
prior close
₹3326.60
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2+0.3+0.3+0.6-0.2+0.9-0.9-1.8-1.2+2.4+2.6———
Up moveDown movePending
AI summary
Ajanta Pharma has received the Establishment Inspection Report (EIR) from the US FDA for its Paithan, Maharashtra manufacturing facility. The cGMP inspection, conducted from 13 April 2026 to 21 April 2026, has been classified as Voluntary Action Indicated (VAI), meaning the facility is in acceptable compliance and no further regulatory action is required. This is a positive regulatory outcome.
Likely market impact
Positive for shareholders: clean US FDA classification removes regulatory overhang and supports continued exports from the Paithan facility.